Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Melanoma 3Neoplasm Metastasis 2Skin Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Interleukins × Dermatologic × Clear all
NCT01856023 2023-12-05

PROCLIVITY02

Clinigen, Inc.

Phase 4 Terminated
29 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT01883323 2019-11-08

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

University Health Network, Toronto

Phase 2 Completed
12 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00553306 2017-02-15

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Fred Hutchinson Cancer Center

Phase 1/2 Completed
10 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡